JP2023530046A - Ｔｎｆファミリーのメンバーの二重標的化のための方法および組合せ - Google Patents

Ｔｎｆファミリーのメンバーの二重標的化のための方法および組合せ Download PDF

Info

Publication number
JP2023530046A
JP2023530046A JP2022560454A JP2022560454A JP2023530046A JP 2023530046 A JP2023530046 A JP 2023530046A JP 2022560454 A JP2022560454 A JP 2022560454A JP 2022560454 A JP2022560454 A JP 2022560454A JP 2023530046 A JP2023530046 A JP 2023530046A
Authority
JP
Japan
Prior art keywords
light
tl1a
binds
molecule
binding domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530046A5 (https=
Inventor
マイケル クロフト，
ラナ ヒーロー，
Original Assignee
ラ ホヤ インスティテュート フォー イムノロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラ ホヤ インスティテュート フォー イムノロジー filed Critical ラ ホヤ インスティテュート フォー イムノロジー
Publication of JP2023530046A publication Critical patent/JP2023530046A/ja
Publication of JP2023530046A5 publication Critical patent/JP2023530046A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2022560454A 2020-04-02 2021-04-01 Ｔｎｆファミリーのメンバーの二重標的化のための方法および組合せ Pending JP2023530046A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063004030P 2020-04-02 2020-04-02
US63/004,030 2020-04-02
PCT/US2021/025453 WO2021202926A1 (en) 2020-04-02 2021-04-01 Methods and combinations for dual targeting of tnf family members

Publications (2)

Publication Number Publication Date
JP2023530046A true JP2023530046A (ja) 2023-07-13
JP2023530046A5 JP2023530046A5 (https=) 2024-04-10

Family

ID=77928094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560454A Pending JP2023530046A (ja) 2020-04-02 2021-04-01 Ｔｎｆファミリーのメンバーの二重標的化のための方法および組合せ

Country Status (4)

Country Link
US (1) US20230159649A1 (https=)
EP (1) EP4126960A4 (https=)
JP (1) JP2023530046A (https=)
WO (1) WO2021202926A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120917045A (zh) * 2023-02-17 2025-11-07 普罗米修斯生物科学公司 治疗皮肤的抗tl1a抗体组合物和方法
WO2024173865A2 (en) * 2023-02-17 2024-08-22 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the kidney
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
TW202545974A (zh) * 2024-01-26 2025-12-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫受體抑制蛋白及相關方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539243A (ja) * 2007-09-18 2010-12-16 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 喘息、肺及び気道の炎症、呼吸器、間質性、肺性および線維性疾患の処置のためのｌｉｇｈｔ阻害剤
JP2016522164A (ja) * 2013-03-27 2016-07-28 セダーズ−シナイ メディカル センター Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
WO2016127059A2 (en) * 2015-02-05 2016-08-11 La Jolla Institute For Allergy And Immunology Light inhibitors for scleroderma and skin fibrotic disease treatment
WO2017077715A1 (en) * 2015-11-02 2017-05-11 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
WO2021049606A1 (ja) * 2019-09-13 2021-03-18 協和キリン株式会社 ＤｃＲ３改変体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317388A1 (en) * 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539243A (ja) * 2007-09-18 2010-12-16 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 喘息、肺及び気道の炎症、呼吸器、間質性、肺性および線維性疾患の処置のためのｌｉｇｈｔ阻害剤
JP2016522164A (ja) * 2013-03-27 2016-07-28 セダーズ−シナイ メディカル センター Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
WO2016127059A2 (en) * 2015-02-05 2016-08-11 La Jolla Institute For Allergy And Immunology Light inhibitors for scleroderma and skin fibrotic disease treatment
WO2017077715A1 (en) * 2015-11-02 2017-05-11 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
WO2021049606A1 (ja) * 2019-09-13 2021-03-18 協和キリン株式会社 ＤｃＲ３改変体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HERRO R. ET AL.: "Shedding LIGHT and TL1A on fibrosis", THE JOURNAL OF IMMUNOLOGY, vol. Volume 204, Issue 1_Supplement, JPN6025022058, 1 May 2020 (2020-05-01), pages 234 - 5, ISSN: 0005801983 *
WAN X. ET AL., JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 89, JPN6025022057, 2003, pages 603 - 612, ISSN: 0005801982 *

Also Published As

Publication number Publication date
EP4126960A1 (en) 2023-02-08
WO2021202926A1 (en) 2021-10-07
EP4126960A4 (en) 2024-11-13
US20230159649A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
JP7351989B2 (ja) 炎症性状態の処置方法
JP2023530046A (ja) Ｔｎｆファミリーのメンバーの二重標的化のための方法および組合せ
JP6031510B2 (ja) 異常な線維芽細胞増殖及び細胞外マトリックスの沈着を特徴とする疾患、症状又はプロセスを予防又は治療する組成物及び方法
US12338283B2 (en) Methods for targeting the immune checkpoint PD1 pathway for treating pulmonary fibrosis
EP3102939A2 (en) AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
Ma et al. Immune and non-immune mediators in the fibrosis pathogenesis of salivary gland in Sjögren’s syndrome
TW201623330A (zh) Ｉｌ－２１抗體
JP7499257B2 (ja) ヌクレアーゼ融合タンパク質によるシェーグレン病の処置
JP7125979B2 (ja) 異所性骨化の治療又は予防のための医薬組成物
KR20170083063A (ko) 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정의 예방 또는 치료용 조성물 및 방법
JP6655547B2 (ja) 慢性肺移植片機能不全（ｃｌａｄ）および特発性肺線維症（ｉｐｆ）を予防または処置するための組成物および方法
US11135223B2 (en) Compositions and methods for inhibiting Dkk-1
CN111741763A (zh) 包含apl型肽的药用组合物
Deng et al. Interleukin-17 family in health and immune diseases: From origin to clinical implications
US20200332258A1 (en) Treatment of type 1 diabetes and autoimmune diseases or disorders
KR20170044171A (ko) 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정의 예방 또는 치료용 조성물 및 방법
CN111655289A (zh) 组合治疗剂
US20150004613A1 (en) Methods for treating hematopoietic malignancies
HK40114368A (zh) 用於治疗嗜酸性粒细胞驱动的疾病和病症的方法和组合物
TW202400647A (zh) 用於治療嗜酸性球驅動之疾病及病症的方法及組成物
Russell The role of macrophage migration inhibitory factor in airways disease
Meyer et al. NK Cells
US20090317357A1 (en) Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents
Raundhal Characterization of Immune Response in Corticosteroid-refractory Severe Asthma in Humans and Mice
Sadeghi The contribution of interleukin-1 and retinoid acid receptor-related orphan receptor alpha to the pathogenesis of epidermolysis bullosa acquisita

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224